This HTML5 document contains 168 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
dbohttp://dbpedia.org/ontology/
n12http://dbpedia.org/resource/File:
foafhttp://xmlns.com/foaf/0.1/
n17http://dbpedia.org/resource/Ledipasvir/
n7https://global.dbpedia.org/id/
dbpedia-ruhttp://ru.dbpedia.org/resource/
dbthttp://dbpedia.org/resource/Template:
rdfshttp://www.w3.org/2000/01/rdf-schema#
n9http://commons.wikimedia.org/wiki/Special:FilePath/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
wikipedia-enhttp://en.wikipedia.org/wiki/
provhttp://www.w3.org/ns/prov#
dbphttp://dbpedia.org/property/
dbchttp://dbpedia.org/resource/Category:
xsdhhttp://www.w3.org/2001/XMLSchema#
wikidatahttp://www.wikidata.org/entity/
dbrhttp://dbpedia.org/resource/

Statements

Subject Item
dbr:Samatasvir
dbo:wikiPageWikiLink
dbr:Discovery_and_development_of_NS5A_inhibitors
Subject Item
dbr:Antiviral_drug
dbo:wikiPageWikiLink
dbr:Discovery_and_development_of_NS5A_inhibitors
Subject Item
dbr:Velpatasvir
dbo:wikiPageWikiLink
dbr:Discovery_and_development_of_NS5A_inhibitors
Subject Item
dbr:Elbasvir
dbo:wikiPageWikiLink
dbr:Discovery_and_development_of_NS5A_inhibitors
Subject Item
dbr:Ledipasvir
dbo:wikiPageWikiLink
dbr:Discovery_and_development_of_NS5A_inhibitors
Subject Item
dbr:Protease_inhibitor_(pharmacology)
dbo:wikiPageWikiLink
dbr:Discovery_and_development_of_NS5A_inhibitors
Subject Item
dbr:Discovery_and_development_of_HIV-protease_inhibitors
dbo:wikiPageWikiLink
dbr:Discovery_and_development_of_NS5A_inhibitors
Subject Item
dbr:Discovery_and_development_of_NS5A_inhibitors
rdfs:label
Ингибиторы белка NS5A Discovery and development of NS5A inhibitors
rdfs:comment
Nonstructural protein 5A (NS5A) inhibitors are direct acting antiviral agents (DAAs) that target viral proteins, and their development was a culmination of increased understanding of the viral life cycle combined with advances in drug discovery technology. However, their mechanism of action is complex and not fully understood. NS5A inhibitors were the focus of much attention when they emerged as a part of the first curative treatment for hepatitis C virus (HCV) infections in 2014. Favorable characteristics have been introduced through varied structural changes, and structural similarities between NS5A inhibitors that are clinically approved are readily apparent. Despite the recent introduction of numerous new antiviral drugs, resistance is still a concern and these inhibitors are therefore Ингибиторы белка NS5A относятся к классу противовирусных препаратов прямого действия.Они направлены на белок NS5A вируса гепатита С.Их развитие является кульминацией более глубокого понимания жизненного цикла вируса. Однако, их механизм действия сложен и не полностью изучен. Ингибиторы белка NS5A должны быть использованы совместно с дополнительными противовирусными препаратами, так как они быстро приводят к развитию мутаций устойчивых к препарату.
foaf:depiction
n9:Symmetrical_structure_two.png n9:Symmetrical_structure_.png n9:Mechanism_of_action_for_NS5A_inhibitors.png n9:Chemical_structure_eight.png n9:Chemical_structure_elleven.png n9:Chemical_structure_four.png n9:Chemical_structure_fourteen.png n9:Chemical_structure_fifteen.png n9:Chemical_structure_five.png n9:HCV_genome.png n9:Chemical_structure_two.png n9:Chemical_structures_of_ns5a_inhibitors.png n9:Chemical_structure_seven.png n9:Chemical_structure_six.png n9:Chemical_structure_nine.png n9:Chemical_structure_one.png n9:Chemical_structure_three.png n9:Chemical_structure_twelve.png n9:Chemical_structure_ten.png n9:Chemical_structure_thirteen.png n9:Unsymmetrical_structure.png
dcterms:subject
dbc:NS5A_inhibitors dbc:Drug_discovery
dbo:wikiPageID
51779654
dbo:wikiPageRevisionID
1100062030
dbo:wikiPageWikiLink
dbr:Symmetry dbr:Protease_inhibitor_(pharmacology) dbr:Endoplasmic_reticulum dbr:Grazoprevir dbr:Ombitasvir dbr:Phenyl dbr:NS3_(HCV) dbr:Lipophilicity dbr:Protease dbr:Liver_disease dbr:Viral_structural_protein dbr:Downregulation_and_upregulation dbr:Viral_life_cycle dbr:Half-life dbr:Viral_protein dbr:Transfection dbr:Screening_(medicine) dbr:Phosphoprotein dbr:Metabolism dbr:Combination_therapy dbr:Drug_development dbr:Adverse_effect dbr:Derivative_(chemistry) dbr:Biosynthesis dbr:Strain_(biology) dbr:Imidazole dbr:Combination_drug dbr:Ribavirin dbr:Pharmacokinetics dbr:Viral_quasispecies n12:Chemical_structures_of_ns5a_inhibitors.png dbr:Cirrhosis dbr:Discovery_and_development_of_HIV-protease_inhibitors n12:Chemical_structure_thirteen.png n12:Chemical_structure_three.png dbr:Fluorene n12:Chemical_structure_twelve.png n12:Chemical_structure_two.png dbr:Positive-sense_single-stranded_RNA_virus n12:Chemical_structure_eight.png n12:Chemical_structure_elleven.png n12:Chemical_structure_fifteen.png n12:Chemical_structure_five.png dbr:Alkyne dbr:Naphthalene n12:Chemical_structure_one.png n12:Chemical_structure_seven.png n12:Chemical_structure_six.png n12:Chemical_structure_ten.png n12:Chemical_structure_four.png n12:Chemical_structure_fourteen.png dbr:Hyperphosphorylation n12:Chemical_structure_nine.png dbr:Food_and_Drug_Administration dbr:Viral_nonstructural_protein dbr:Genotype dbr:Antimicrobial_resistance dbr:Hepatocyte dbr:Proline_rich_protein dbr:Hepatitis_C dbr:NS4A dbr:NS4B dbr:Zinc_finger dbr:Cellular_stress_response dbc:NS5A_inhibitors dbr:Dextrorotation_and_levorotation dbr:NS5A dbr:Hepatitis_C_virus dbr:Velpatasvir dbr:NS5B dbc:Drug_discovery dbr:Amine dbr:Sofosbuvir n12:Symmetrical_structure_.png dbr:Hepatocellular_carcinoma dbr:Elbasvir n12:Symmetrical_structure_two.png dbr:Mechanism_of_action dbr:Daclatasvir dbr:Phosphorylation dbr:NS2_(HCV) dbr:Serine dbr:Drug_resistance n12:Mechanism_of_action_for_NS5A_inhibitors.png dbr:Bioavailability dbr:Aryl dbr:Peginterferon_alfa-2a dbr:Ledipasvir dbr:Molecule n17:sofosbuvir dbr:Resistance_mutation_(virology) dbr:Viral_replication dbr:Phosphatidylinositol_4-phosphate dbr:Pegylated_interferon dbr:Potency_(pharmacology) dbr:Kinase dbr:Apoptosis dbr:Hydrophile dbr:Genome dbr:Chronic_kidney_disease dbr:Amino_acid dbr:N-terminus dbr:Benzimidazole dbr:Asymmetry dbr:Amphiphile dbr:Cell_cycle dbr:Cloning n12:HCV_genome.png dbr:Helix n12:Unsymmetrical_structure.png dbr:Cell_culture dbr:Proline dbr:Substitution_reaction
owl:sameAs
n7:2d2HK wikidata:Q28209265 dbpedia-ru:Ингибиторы_белка_NS5A
dbp:wikiPageUsesTemplate
dbt:Drug_design dbt:Font_color dbt:Reflist dbt:Columns-list
dbo:thumbnail
n9:HCV_genome.png?width=300
dbo:abstract
Nonstructural protein 5A (NS5A) inhibitors are direct acting antiviral agents (DAAs) that target viral proteins, and their development was a culmination of increased understanding of the viral life cycle combined with advances in drug discovery technology. However, their mechanism of action is complex and not fully understood. NS5A inhibitors were the focus of much attention when they emerged as a part of the first curative treatment for hepatitis C virus (HCV) infections in 2014. Favorable characteristics have been introduced through varied structural changes, and structural similarities between NS5A inhibitors that are clinically approved are readily apparent. Despite the recent introduction of numerous new antiviral drugs, resistance is still a concern and these inhibitors are therefore always used in combination with other drugs. Ингибиторы белка NS5A относятся к классу противовирусных препаратов прямого действия.Они направлены на белок NS5A вируса гепатита С.Их развитие является кульминацией более глубокого понимания жизненного цикла вируса. Однако, их механизм действия сложен и не полностью изучен. Ингибиторы белка NS5A должны быть использованы совместно с дополнительными противовирусными препаратами, так как они быстро приводят к развитию мутаций устойчивых к препарату.
prov:wasDerivedFrom
wikipedia-en:Discovery_and_development_of_NS5A_inhibitors?oldid=1100062030&ns=0
dbo:wikiPageLength
51395
foaf:isPrimaryTopicOf
wikipedia-en:Discovery_and_development_of_NS5A_inhibitors
Subject Item
dbr:Hepatitis_C_virus
dbo:wikiPageWikiLink
dbr:Discovery_and_development_of_NS5A_inhibitors
Subject Item
dbr:Odalasvir
dbo:wikiPageWikiLink
dbr:Discovery_and_development_of_NS5A_inhibitors
Subject Item
dbr:Ombitasvir
dbo:wikiPageWikiLink
dbr:Discovery_and_development_of_NS5A_inhibitors
Subject Item
dbr:Ravidasvir
dbo:wikiPageWikiLink
dbr:Discovery_and_development_of_NS5A_inhibitors
Subject Item
dbr:NS5A_(hepacivirus)
dbo:wikiPageWikiLink
dbr:Discovery_and_development_of_NS5A_inhibitors
Subject Item
wikipedia-en:Discovery_and_development_of_NS5A_inhibitors
foaf:primaryTopic
dbr:Discovery_and_development_of_NS5A_inhibitors